Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis

Vascular Pharmacology

Volumn 63, Issue 1, 2014, Pages 19-28

  Kwon, Hyuk Min ^a   Hur, Sung Mo ^b   Park, Keon Young ^b   Kim, Chun Ki ^b   Kim, Yong Man ^c   Kim, Hyun Soo ^c   Shin, Ha Cheol ^c   Won, Moo Ho ^b   Ha, Kwon Soo ^a   Kwon, Young Guen ^d   Lee, Dong Heon ^a   Kim, Young Myeong ^b  

^a Kangwon National University College of Medicine   (South Korea)

^b Kangwon National University   (South Korea)

^c Pharmicell Co Ltd   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

Angiogenesis; HUVEC; Mesenchymal stem cell; Paracrine factor

Indexed keywords

ANGIOGENIC FACTOR; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR AA; SCATTER FACTOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; CYTOKINE; SIGNAL PEPTIDE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMB ISCHEMIA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; ADULT; ANIMAL; C57BL MOUSE; HINDLIMB; ISCHEMIA; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; PARACRINE SIGNALING; PHYSIOLOGY; VASCULARIZATION;

ADULT; ANIMALS; CHEMOKINE CCL2; CYTOKINES; HINDLIMB; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; ISCHEMIA; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PARACRINE COMMUNICATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908046151     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.06.004     Document Type: Article

References (48)

1. Rafii S., Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003, 9:702-712.
2. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
3. Schachinger V., Erbs S., Elsasser A., Haberbosch W., Hambrecht R., Yu J., et al. Intracoronary bone marrow derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
4. Tse H.F., Kwong Y.L., Chan J.K., Lo G., Ho C.L., Lau C.P. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003, 361:47-49.
5. Murohara T., Ikeda H., Duan J., Shintani S., Sasaki K., Eguchi H., et al. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 2000, 105:1527-1536.
6. Yousef M., Schannwell C.M., Kostering M., Zeus T., Brehm M., Strauer B.E. The BALANCE Study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J Am Coll Cardiol 2009, 53:2262-2269.
7. Przybyt E., Harmsen M.C. Mesenchymal stem cells: promising for myocardial regeneration?. Curr Stem Cell Res Ther 2013, 8:270-277.
8. van Laake L.W., Passier R., denOuden K., Schreurs C., Monshouwer-Kloots J., Ward-van Oostwaard D., et al. Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. Stem Cell Res 2009, 3:106-112.
9. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004, 95:9-20.
10. Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005, 11:367-368.
11. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006, 98:1076-1084.
12. Razban V., Lotfi A.S., Soleimani M., Ahmadi H., Massumi M., Khajeh S., et al. HIF-1α overexpression induces angiogenesis in mesenchymal stem cells. Biores Open Access 2012, 1:174-183.
13. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006, 20:661-669.
14. Huang X.P., Sun Z., Miyagi Y., McDonald Kinkaid H., Zhang L., Weisel R.D., et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010, 122:2419-2429.
15. Choi Y.K., Kim C.K., Lee H., Jeoung D., Ha K.S., Kwon Y.G., et al. Carbon monoxide promotes VEGF expression by increasing HIF-1α protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein. J Biol Chem 2010, 285:32116-32125.
16. Baek Y.Y., Cho D.H., Choe J., Lee H., Jeoung D., Ha K.S., et al. Extracellular taurine induces angiogenesis by activating ERK-, Akt-, and FAK-dependent signal pathways. Eur J Pharmacol 2012, 674:188-199.
17. Min J.K., Han K.Y., Kim E.C., Kim Y.M., Lee S.W., Kim O.H., et al. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res 2004, 64:644-651.
18. Hung S.C., Pochampally R.R., Chen S.C., Hsu S.C., Prockop D.J. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007, 25:2363-2370.
19. Folkman J. Angiogenesis. Annu Rev Med 2006, 57:1-18.
20. Taylor C.T., Kent B.D., Crinion S.J., McNicholas W.T., Ryan S. Human adipocytes are highly sensitive to intermittent hypoxia induced NF-κB activity and subsequent inflammatory gene expression. Biochem Biophys Res Commun 2014, 447:660-665.
21. Hata T., Takahashi M., Hida S., Kawaguchi M., Kashima Y., Usui F., et al. Critical role of Th17 cells in inflammation and neovascularization after ischaemia. Cardiovasc Res 2011, 90:364-372.
22. Heil M., Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004, 95:449-458.
23. Al-Khaldi A., Al-Sabti H., Galipeau J., Lachapelle K. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann Thorac Surg 2003, 75:204-209.
24. Iwase T., Nagaya N., Fujii T., Itoh T., Murakami S., Matsumoto T., et al. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res 2005, 66:543-551.
25. Tang Y.L., Zhao Q., Zhang Y.C., Cheng L., Liu M., Shi J., et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 2004, 117:3-10.
26. Reyes M., Dudek A., Jahagirdar B., Koodie L., Marker P.H., Verfaillie C.M. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002, 109:337-346.
27. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
28. Nagaya N., Fujii T., Iwase T., Ohgushi H., Itoh T., Uematsu M., et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol 2004, 287:H2670-H2676.
29. Jaquet K., Krause K.T., Denschel J., Faessler P., Nauerz M., Geidel S., et al. Reduction of myocardial scar size after implantation of mesenchymal stem cells in rats: what is the mechanism?. Stem Cells Dev 2005, 14:299-309.
30. Miyahara Y., Nagaya N., Kataoka M., Yanagawa B., Tanaka K., Hao H., et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006, 12:459-465.
31. Massague J., Blain S.W., Lo R.S. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309.
32. Vinals F., Pouyssegur J. Transforming growth factor β1 (TGF-β1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-α signaling. Mol Cell Biol 2001, 21:7218-7230.
33. Montesano R., Matsumoto K., Nakamura T., Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991, 67:901-908.
34. Boomsma R.A., Geenen D.L. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS One 2012, 7:e35685.
35. Park K.S., Kim Y.S., Kim J.H., Choi B., Kim S.H., Tan A.H., et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation 2010, 89:509-517.
36. Xu S., Zhu J., Yu L., Fu G. Endothelial progenitor cells: current development of their paracrine factors in cardiovascular therapy. J Cardiovasc Pharmacol 2012, 59:387-396.
37. Timmers L., Lim S.K., Hoefer I.E., Arslan F., Lai R.C., van Oorschot A.A., et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011, 6:206-214.
38. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
39. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004, 94:678-685.
40. Ito W.D., Arras M., Winkler B., Scholz D., Schaper J., Schaper W. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 1997, 80:829-837.
41. Takeshita S., Zheng L.P., Brogi E., Kearney M., Pu L.-Q., Bunting S., et al. Therapeutic angiogenesis: a single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994, 93:662-670.
42. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
43. Araki R., Uda M., Hoki Y., Sunayama M., Nakamura M., Ando S., et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013, 494:100-104.
44. Guha P., Morgan J.W., Mostoslavsky G., Rodrigues N.P., Boyd A.S. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013, 12:407-412.
45. Dhingra S., Huang X.P., Li R.K. Challenges in allogeneic mesenchymal stem cell-mediated cardiac repair. Trends Cardiovasc Med 2010, 20:263-268.
46. Friis T., Haack-Sørensen M., Hansen S.K., Hansen L., Bindslev L., Kastrup J. Comparison of mesenchymal stromal cells from young healthy donors and patients with severe chronic coronary artery disease. Scand J Clin Lab Invest 2011, 71:193-202.
47. Chen H.W., Chen H.Y., Wang L.T., Wang F.H., Fang L.W., Lai H.Y., et al. Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol 2013, 190:5065-5077.
48. Elman J.S., Li M., Wang F., Gimble J.M., Parekkadan B. A comparison of adipose and bone marrow-derived mesenchymal stromal cell secreted factors in the treatment of systemic inflammation. J Inflamm (Lond) 2014, 11. 10.1186/1476-9255-11-1.